Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
TEVA NEUROSCIENCE, INC. et al v. WATSON PHARMA, INC. et al
Case Number:
2:10-cv-05078
Court:
Nature of Suit:
Judge:
Firms
- Buchanan Ingersoll
- Connell Foley
- Duane Morris
- Latham & Watkins
- Lite DePalma
- Mandelbaum Barrett
- Patunas Law
- Perkins Coie
- Rivkin Radler
- Saiber LLC
- Troutman Pepper
Companies
Sectors & Industries:
-
December 16, 2013
Teva Wins Ban On Mylan Parkinson's Generic
A New Jersey federal judge on Friday barred Mylan Inc. from manufacturing, importing or selling its own version of Teva Pharmaceutical Industries Ltd.'s brand-name treatment for Parkinson's disease, Azilect, for more than three years, after the generic-drug maker stipulated its proposed generic infringed a Teva patent.
-
May 23, 2013
Watson, Apotex Settle Azilect Patent Infringement Suit
A New Jersey federal judge on Thursday dismissed Teva Pharmaceutical Industries Ltd.'s claims that generic-drug makers Watson Laboratories Inc. and Apotex Corp. infringed its patents for the Parkinson's disease drug Azilect, saying the parties have reached confidential settlement and licensing agreements.
-
April 30, 2013
Teva, Orchid Settle Patent Dispute Over Azilect
Teva Pharmaceutical Industries Ltd. and Orchid Chemicals & Pharmaceuticals Ltd. have reached a settlement in patent and antitrust litigation over Teva's Parkinson's disease drug Azilect, resulting in dismissal of all claims and counterclaims between the two companies, according to documents filed in New Jersey federal court Tuesday.
-
February 21, 2013
Teva Slams Antitrust Claims In Azilect Patent Row
Teva Pharmaceutical Industries Ltd. said its patent for its Parkinson's disease drug Azilect is valid and would-be generic competitors are overreaching in claims that it broke antitrust laws to secure the patent through fraud and sham suits, according to a pretrial brief filed Wednesday in New Jersey federal court.
-
July 14, 2011
Teva Drops Azilect Patent Claim Against Watson, Mylan
A New Jersey federal judge on Wednesday signed off on the dismissal of one of two infringement claims Teva Pharmaceutical Industries Ltd. had brought against Watson Laboratories Inc. and Mylan Inc. over patents for Teva's Parkinson's disease drug Azilect.
-
March 07, 2011
Watson, Orchid Defenses Live In Generic Azilect Row
A New Jersey federal judge on Thursday refused to toss Watson Laboratories Inc. and Orchid Chemicals & Pharmaceuticals Ltd.'s inequitable conduct defenses in Teva Pharmaceutical Industries Ltd.'s suit over efforts to make a generic version of Parkinson's disease drug Azilect.
-
February 25, 2011
Mylan Claims Fall In IP Suit Over Generic Azilect
A New Jersey federal judge on Tuesday tossed generics maker Mylan Inc.'s inequitable conduct defenses in a patent infringement suit brought by Teva Pharmaceutical Industries Ltd. over efforts to make a copycat version of Parkinson's disease drug Azilect.